Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux for VTE prevention after hip replacement
NCT00320398Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Primary completion
- Jul 2006
- Modality
- Allosteric Modulators
01
Overview
A Phase 3 trial of fondaparinux in venous thromboembolism (VTE), sponsored by GSK. Started Jan 2006; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00320398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320398.